Epstein Secrets

rope Acquisitions and is based in London. Since joining Blackstone in 2011, Mr. Seppala has been involved in a number of Blackstone's investments in the United States and in Europe. Prior to joining Blackstone in 2011, Mr. Seppala was a Vice President at Goldman Sachs & Co, where he spent 10 years focused on equit

nds. Prior to joining Blackstone, Mr. Nash was with Merrill Lynch from 1997 to 2007 where he led the finn's Real Estate Principal Investment Group - Americas. Prior to 1997, Mr. Nash held various positions with Barclays Bank, Bank of Nova Scotia and Dcloitte Haskins & Sells. Mr. Nash received a B.S. in Ac

me, certain income from sales and services), regardless of cash distributions from the company. In addition, gain on the sale of the CFC's stock by a United States Shareholder (during the period that the corporation is a CFC and thereafter for a five-year period) would be classified in whole or in part as a div

g Balfour, Mr. Myers was an Associate Director in the Bear Stearns Real Estate group. Mr. Myers received a BSc with Honors in Civil Engineering from the University of Cape Town and an MBA from Columbia University. James Seppala is the Head of Europe Acquisitions and is based in London. Since joining Blackstone in 2011, Mr

hin the securities industry—Sales, Trading, Research and Management— across a 22 year career. Most recently Mr Homick was Head of Fixed Income Sales— Americas for Nomura Securities. Mr Homick holds a B.S. in business administration from Georgetown University and an M.B.A. from the University of Michigan.

s trading, operations and technology areas. Mr. Meskin has an M.B.A. in finance from New York University and a Master's in Information Systems from the University of Cape Town, South Africa. John Novogratz Global Head of Marketing, Investor Relations and Product Development - Joined in 2009 Mr. Novogratz is responsible f

s Shareholders under the CFC rules, and (ii) will be subject to the Section 1248 recharacterization rule described above. In addition, if the Fund is a United States Shareholder of a CFC and a U.S. Partner disposes of its Limited Partner Interest, that Partner generally will recognize income under Section 751 of t

in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Ho